Active ingredient: Imiglucerase

How long you have been taking the medicine?
advertisement

Imiglucerase uses


INDICATIONS AND USAGE

Cerezyme® (imiglucerase for injection) is indicated for long-term enzyme replacement therapy for pediatric and adult patients with a confirmed diagnosis of Type 1 Gaucher disease that results in one or more of the following conditions:

a. anemia

b. thrombocytopenia

c. bone disease

d. hepatomegaly or splenomegaly

CONTRAINDICATIONS

There are no known contraindications to the use of Cerezyme® (imiglucerase for injection). Treatment with Imiglucerase should be carefully re-evaluated if there is significant clinical evidence of hypersensitivity to the product.

WARNINGS

Approximately 15% of patients treated and tested to date have developed IgG antibody to Cerezyme® (imiglucerase for injection) during the first year of therapy. Patients who developed IgG antibody did so largely within 6 months of treatment and rarely developed antibodies to Imiglucerase after 12 months of therapy. Approximately 46% of patients with detectable IgG antibodies experienced symptoms of hypersensitivity.

Patients with antibody to Imiglucerase have a higher risk of hypersensitivity reaction. Conversely, not all patients with symptoms of hypersensitivity have detectable IgG antibody. It is suggested that patients be monitored periodically for IgG antibody formation during the first year of treatment.

Treatment with Imiglucerase should be approached with caution in patients who have exhibited symptoms of hypersensitivity to the product.

Anaphylactoid reaction has been reported in less than 1% of the patient population. Further treatment with Imiglucerase should be conducted with caution. Most patients have successfully continued therapy after a reduction in rate of infusion and pretreatment with antihistamines and/or corticosteroids.

advertisement

PRECAUTIONS

General

In less than 1% of the patient population, pulmonary hypertension and pneumonia have also been observed during treatment with Cerezyme®. Pulmonary hypertension and pneumonia are known complications of Gaucher disease and have been observed both in patients receiving and not receiving Imiglucerase. No causal relationship with Imiglucerase has been established. Patients with respiratory symptoms in the absence of fever should be evaluated for the presence of pulmonary hypertension.

Therapy with Imiglucerase should be directed by physicians knowledgeable in the management of patients with Gaucher disease.

Caution may be advisable in administration of Imiglucerase to patients previously treated with Ceredase® (alglucerase injection) and who have developed antibody to Ceredase® or who have exhibited symptoms of hypersensitivity to Ceredase®.

Carcinogenesis, Mutagenesis, Impairment of Fertility

Studies have not been conducted in either animals or humans to assess the potential effects of Cerezyme® (imiglucerase for injection) on carcinogenesis, mutagenesis, or impairment of fertility.

Teratogenic Effects: Pregnancy Category C

Animal reproduction studies have not been conducted with Cerezyme®. It is also not known whether Imiglucerase can cause fetal harm when administered to a pregnant woman or can affect reproductive capacity. Imiglucerase should not be administered during pregnancy except when the indication and need are clear and the potential benefit is judged by the physician to substantially justify the risk.

Nursing Mothers

It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Cerezyme® (imiglucerase for injection) is administered to a nursing woman.

Pediatric Use

The safety and effectiveness of Cerezyme® (imiglucerase for injection) have been established in patients between 2 and 16 years of age. Use of Imiglucerase in this age group is supported by evidence from adequate and well-controlled studies of Imiglucerase and Ceredase® (alglucerase injection) in adults and pediatric patients, with additional data obtained from the medical literature and from long-term postmarketing experience. Imiglucerase has been administered to patients younger than 2 years of age, however the safety and effectiveness in patients younger than 2 have not been established.

advertisement

ADVERSE REACTIONS

Since the approval of Cerezyme® (imiglucerase for injection) in May 1994, Genzyme has maintained a worldwide post-marketing database of spontaneously reported adverse events and adverse events discussed in the medical literature. The percentage of events for each reported adverse reaction term has been calculated using the number of patients from these sources as the denominator for total patient exposure to Imiglucerase since 1994. Actual patient exposure is difficult to obtain due to the voluntary nature of the database and the continuous accrual and loss of patients over that span of time. The actual number of patients exposed to Imiglucerase since 1994 is likely to be greater than estimated from these voluntary sources and, therefore, the percentages calculated for the frequencies of adverse reactions are most likely greater than the actual incidences.

Experience in patients treated with Cerezyme® has revealed that approximately 13.8% of patients experienced adverse events which were judged to be related to Imiglucerase administration and which occurred with an increase in frequency. Some of the adverse events were related to the route of administration. These include discomfort, pruritus, burning, swelling or sterile abscess at the site of venipuncture. Each of these events was found to occur in < 1% of the total patient population.

Symptoms suggestive of hypersensitivity have been noted in approximately 6.6% of patients. Onset of such symptoms has occurred during or shortly after infusions; these symptoms include pruritus, flushing, urticaria, angioedema, chest discomfort, dyspnea, coughing, cyanosis, and hypotension. Anaphylactoid reaction has also been reported (see WARNINGS ). Each of these events was found to occur in < 1.5% of the total patient population. Pre-treatment with antihistamines and/or corticosteroids and reduced rate of infusion have allowed continued use of Imiglucerase in most patients.

Additional adverse reactions that have been reported in approximately 6.5% of patients treated with Imiglucerase include: nausea, abdominal pain, vomiting, diarrhea, rash, fatigue, headache, fever, dizziness, chills, backache, and tachycardia. Each of these events was found to occur in < 1.5% of the total patient population.

Incidence rates cannot be calculated from the spontaneously reported adverse events in the post-marketing database. From this database, the most commonly reported adverse events in children (defined as ages 2 – 12 years) included dyspnea, fever, nausea, flushing, vomiting, and coughing, whereas in adolescents (>12 – 16 years) and in adults (>16 years) the most commonly reported events included headache, pruritis, and rash.

In addition to the adverse reactions that have been observed in patients treated with Imiglucerase, transient peripheral edema has been reported for this therapeutic class of drug.

advertisement

OVERDOSE

Experience with doses up to 240 U/kg every 2 weeks have been reported. At that dose there have been no reports of obvious toxicity.

DOSAGE AND ADMINISTRATION

Cerezyme® (imiglucerase for injection) is administered by intravenous infusion over 1-2 hours. Dosage should be individualized to each patient. Initial dosages range from 2.5 U/kg of body weight 3 times a week to 60 U/kg once every 2 weeks. 60 U/kg every 2 weeks is the dosage for which the most data are available. Disease severity may dictate that treatment be initiated at a relatively high dose or relatively frequent administration. Dosage adjustments should be made on an individual basis and may increase or decrease, based on achievement of therapeutic goals as assessed by routine comprehensive evaluations of the patient's clinical manifestations.

Cerezyme® should be stored at 2-8°C (36-46°F). After reconstitution, Imiglucerase should be inspected visually before use. Because this is a protein solution, slight flocculation (described as thin translucent fibers) occurs occasionally after dilution. The diluted solution may be filtered through an in-line low protein-binding 0.2 μm filter during administration. Any vials exhibiting opaque particles or discoloration should not be used. DO NOT USE Imiglucerase after the expiration date on the vial.

On the day of use, after the correct amount of Imiglucerase to be administered to the patient has been determined, the appropriate number of vials are each reconstituted with Sterile Water for Injection, USP. The final concentrations and administration volumes are provided in the following table:

200 Unit Vial 400 Unit Vial
Sterile water for reconstitution 5.1 mL 10.2 mL
Final volume of reconstituted product 5.3 mL 10.6 mL
Concentration after reconstitution 40 U/mL 40 U/mL
Withdrawal volume 5.0 mL 10.0 mL
Units of enzyme within final volume 200 units 400 units

A nominal 5.0 mL for the 200 unit vial (10.0 mL for the 400 unit vial) is withdrawn from each vial. The appropriate amount of Imiglucerase for each patient is diluted with 0.9% Sodium Chloride Injection, USP, to a final volume of 100 – 200 mL. Imiglucerase is administered by intravenous infusion over 1-2 hours. Aseptic techniques should be used when diluting the dose. Since Imiglucerase does not contain any preservative, after reconstitution, vials should be promptly diluted and not stored for subsequent use. Imiglucerase, after reconstitution, has been shown to be stable for up to 12 hours when stored at room temperature (25°C) and at 2-8°C. Imiglucerase, when diluted, has been shown to be stable for up to 24 hours when stored at 2-8°C.

Relatively low toxicity, combined with the extended time course of response, allows small dosage adjustments to be made occasionally to avoid discarding partially used bottles. Thus, the dosage administered in individual infusions may be slightly increased or decreased to utilize fully each vial as long as the monthly administered dosage remains substantially unaltered.

HOW SUPPLIED

Cerezyme® (imiglucerase for injection) is supplied as a sterile, non-pyrogenic, lyophilized product. It is available as follows:

200 Units per Vial NDC 58468-1983-1

400 Units per Vial NDC 58468-4663-1

Store at 2-8°C (36-46°F).

Rx only

Cerezyme® (imiglucerase for injection) is manufactured by:

Genzyme Corporation

500 Kendall Street

Cambridge, MA 02142 USA

Certain manufacturing operations may have been performed by other firms.

Imiglucerase and Genzyme are registered trademarks of Genzyme Corporation.

6LE005D

NDC 58468-1983-1

Imiglucerase®

Imiglucerase for injection

200 Units

For Intravenous infusion only

genzyme

NDC 58468-4663-1

Imiglucerase®

Imiglucerase for injection

400 Units

For Intravenous infusion only

genzyme

Imiglucerase available forms, composition, doses:


Indications and Usages:

ATC codes:


ICD-10 codes:


Imiglucerase destination | category:


advertisement

Drugs with same active ingredients (Pharmaceutical companies):


References

  1. Dailymed."CEREZYME (IMIGLUCERASE) INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION [GENZYME CORPORATION]". https://dailymed.nlm.nih.gov/dailym... (accessed August 28, 2018).
  2. "Imiglucerase". https://pubchem.ncbi.nlm.nih.gov/su... (accessed August 28, 2018).
  3. "Velaglucerase alfa - DrugBank". http://www.drugbank.ca/drugs/DB0672... (accessed August 28, 2018).

Frequently asked Questions

Can i drive or operate heavy machine after consuming Imiglucerase?

Depending on the reaction of the Imiglucerase after taken, if you are feeling dizziness, drowsiness or any weakness as a reaction on your body, Then consider Imiglucerase not safe to drive or operate heavy machine after consumption. Meaning that, do not drive or operate heavy duty machines after taking the capsule if the capsule has a strange reaction on your body like dizziness, drowsiness. As prescribed by a pharmacist, it is dangerous to take alcohol while taking medicines as it exposed patients to drowsiness and health risk. Please take note of such effect most especially when taking Primosa capsule. It's advisable to consult your doctor on time for a proper recommendation and medical consultations.

Is Imiglucerase addictive or habit forming?

Medicines are not designed with the mind of creating an addiction or abuse on the health of the users. Addictive Medicine is categorically called Controlled substances by the government. For instance, Schedule H or X in India and schedule II-V in the US are controlled substances.

Please consult the medicine instruction manual on how to use and ensure it is not a controlled substance.In conclusion, self medication is a killer to your health. Consult your doctor for a proper prescription, recommendation, and guidiance.

advertisement

Review

sdrugs.com conducted a study on Imiglucerase, and the result of the survey is set out below. It is noteworthy that the product of the survey is based on the perception and impressions of the visitors of the website as well as the views of Imiglucerase consumers. We, as a result of this, advice that you do not base your therapeutic or medical decisions on this result, but rather consult your certified medical experts for their recommendations.

Visitor reports

Visitor reported useful

No survey data has been collected yet

Visitor reported side effects

No survey data has been collected yet

Visitor reported price estimates

No survey data has been collected yet

Visitor reported frequency of use

No survey data has been collected yet

Visitor reported doses

No survey data has been collected yet

Visitor reported time for results

No survey data has been collected yet

Visitor reported administration

No survey data has been collected yet

Visitor reported age

No survey data has been collected yet

Visitor reviews


There are no reviews yet. Be the first to write one!


Your name: 
Email: 
Spam protection:  < Type 29 here

The information was verified by Dr. Rachana Salvi, MD Pharmacology

© 2002 - 2024 "sdrugs.com". All Rights Reserved